AI Article Synopsis
- The first monoclonal antibody therapy for Alzheimer's disease was approved by the FDA in 2021, shifting treatment from just managing symptoms to actively reducing amyloid β plaque.
- While these therapies present promising advancements, they also carry risks such as amyloid-related imaging abnormalities (ARIA), including edemas and hemorrhages.
- A case study of a 64-year-old woman treated with donanemab highlights the need for emergency radiologists to be skilled in recognizing ARIA to provide effective care for patients on these new therapies.
Article Abstract
Since the 2021 FDA approval of the first monoclonal antibody (MAB) therapy for Alzheimer's disease (AD), treatment has progressed from symptom management to targeting and reducing amyloid β plaque burden. While these therapies offer hope of altering the disease course, they come with risks, such as amyloid-related imaging abnormalities (ARIA), which include ARIA-E (edema and effusion) and ARIA-H (hemorrhage). This report details the case of a 64-year-old woman undergoing donanemab treatment who developed severe ARIA, characterized by extensive vasogenic edema and multiple microhemorrhages. The increasing use of MABs necessitates heightened awareness and expertise among emergency radiologists to identify findings of ARIA effectively, ensuring timely and appropriate care for patients undergoing these novel therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10140-024-02286-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!